The outlook of companies tied to the drug's past presents a complex investment scenario . While the initial boom generated substantial profits , generic alternatives have significantly eroded sales . Investing in connected pharmaceutical companies now requires a thorough assessment of proprietary safeguards, evolving healthcare trends , and Adult t